The Tailored EDVTM trial: A phase I feasibility study evaluating EGFR-targeted EDVTM nanocells as a therapy platform in patients with refractory advanced solid tumours

被引：1
|
作者：
Clarke, S. [1 ]
Sidhu, S. [2 ]
Pavlakis, N. [1 ]
Brahmbhatt, H. [3 ]
Macdiarmid, J. [3 ]
机构：
[1] Univ Sydney, Northern Canc Inst, Sydney, NSW, Australia
[2] Univ Sydney, Endocrine Surg Unit, Sydney, NSW, Australia
[3] EnGeneIC, Biotechnol, Sydney, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.55
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
412TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells
    Ganju, Vinod
    Marx, Gavin
    Pattison, Scott
    Amaro-Mugridge, Nancy B.
    Zhao, Jing-Ting
    Williams, Bryan R. G.
    MacDiarmid, Jennifer A.
    Brahmbhatt, Himanshu
    CLINICAL CANCER RESEARCH, 2024, 30 (02) : 304 - 314
  • [2] Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors
    Kao, Chien-Chang
    Ho, Ching-Liang
    Yang, Ming-Hsin
    Tsai, Yi-Ta
    Liu, Shu-Yu
    Chang, Ping-Ying
    Wu, Yi-Ying
    Chen, Jia-Hong
    Yehn, Ren-Hua
    Dai, Ming-Shen
    Chen, Yeu-Chin
    Sun, Guang-Huan
    Cha, Tai-Lung
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (08)
  • [3] Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours
    Awada, Ahmad
    Hendlisz, Alain
    Christensen, Olaf
    Lathia, Chetan D.
    Bartholomeus, Sylvie
    Lebrun, Fabienne
    de Valeriola, Dominique
    Brendel, Erich
    Radtke, Martin
    Delaunoit, Thierry
    Piccart-Gebhart, Martine
    Gil, Thierry
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (04) : 465 - 474
  • [4] A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours
    Harb, W.
    Patnaik, A.
    Mahalingam, D.
    Liu, J.
    Wen, P. Y.
    Shapiro, G. I.
    Bullock, A. J.
    Juric, D.
    Zheng, L.
    Moore, K.
    Patel, M.
    Guttendorf, R.
    Wang, S.
    Kerstein, K.
    Berk, G.
    Cieslewicz, M. J.
    Watnick, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
    Lieu, Christopher
    Chow, Laura
    Pierson, A. Scott
    Eckhardt, S. Gail
    O'Bryant, Cindy L.
    Morrow, Mark
    Tran, Zung Vu
    Wright, John J.
    Gore, Lia
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (01) : 53 - 62
  • [6] A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
    Christopher Lieu
    Laura Chow
    A. Scott Pierson
    S. Gail Eckhardt
    Cindy L. O’Bryant
    Mark Morrow
    Zung Vu Tran
    John J. Wright
    Lia Gore
    Investigational New Drugs, 2009, 27 : 53 - 62
  • [7] Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours
    Ruth Plummer
    Henk M. Verheul
    Filip Y. F. L. De Vos
    Karin Leunen
    L. Rhoda Molife
    Christian Rolfo
    Peter Grundtvig-Sørensen
    Jacques De Grève
    Sylvie Rottey
    Guy Jerusalem
    Antoine Italiano
    James Spicer
    Luc Dirix
    Carsten Goessl
    Joseph Birkett
    Stuart Spencer
    Maria Learoyd
    Christopher Bailey
    Emma Dean
    Advances in Therapy, 2018, 35 : 1945 - 1964
  • [8] Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours
    Plummer, Ruth
    Verheul, Henk M.
    De Vos, Filip Y. F. L.
    Leunen, Karin
    Molife, L. Rhoda
    Rolfo, Christian
    Grundtvig-Sorensen, Peter
    De Greve, Jacques
    Rottey, Sylvie
    Jerusalem, Guy
    Italiano, Antoine
    Spicer, James
    Dirix, Luc
    Goessl, Carsten
    Birkett, Joseph
    Spencer, Stuart
    Learoyd, Maria
    Bailey, Christopher
    Dean, Emma
    ADVANCES IN THERAPY, 2018, 35 (11) : 1945 - 1964
  • [9] A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
    Michael J. Pishvaian
    Rebecca Slack
    Eunice Y. Koh
    Jan H. Beumer
    Marion L. Hartley
    Ion Cotarla
    John Deeken
    Aiwu Ruth He
    Jimmy Hwang
    Shakun Malik
    Kashif Firozvi
    Minetta Liu
    Beth Elston
    Sandy Strychor
    Merrill J. Egorin
    John L. Marshall
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 843 - 853
  • [10] A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
    Pishvaian, Michael J.
    Slack, Rebecca
    Koh, Eunice Y.
    Beumer, Jan H.
    Hartley, Marion L.
    Cotarla, Ion
    Deeken, John
    He, Aiwu Ruth
    Hwang, Jimmy
    Malik, Shakun
    Firozvi, Kashif
    Liu, Minetta
    Elston, Beth
    Strychor, Sandy
    Egorin, Merrill J.
    Marshall, John L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 843 - 853
12345